Heidi Crayton, MD, and Maria Lopes, MD, discuss the most recent 2018 guidelines for multiple sclerosis treatment, emphasizing the need for updated guidelines, particularly in the payer space, to ...

A simple algorithm to aid in the selection of appropriate disease modifying therapies (DMTs) reduces racial disparities in patients with relapsing multiple sclerosis (MS), early new research showed.

A simple treatment algorithm may help reduce treatment disparities for Hispanic and Black people with multiple sclerosis (MS), according to a preliminary study released today, March 3, 2025, that will ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

LOS ANGELES — New guidelines on the use of disease-modifying therapies (DMTs) in patients with multiple sclerosis (MS) provide updated guidance on starting, switching, and stopping treatment and ...

Heidi Crayton, MD, discusses the rationale for investigating Bruton tyrosine kinase inhibitors (BTKis) as a treatment for patients with multiple sclerosis and the current stage of development for ...

A registry study led by the University of Oulu examined the early-stage treatment of relapsing-remitting multiple sclerosis (MS) in Finland between 2013 and 2022. According to the study published in ...

New research presented today at ECTRIMS 2024 reveals that initiating monoclonal antibody therapy during childhood, rather than delaying treatment until early adulthood, significantly reduces long-term ...

Significantly higher levels of HRQoL were reported in patients who lived in cities, had lower MS severity and fatigue, had higher cognitive processing speed, and had achieved higher educational ...